文献速递肝病消化道肿瘤与早癌

FGF19/FGFR4介导的ETV4升高通过上调PD-L1和CCL2促进肝细胞癌转移

FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
PubMed 文献 · J Hepatol · 2023-03-11

本研究利用PLC/PRF/5、MHCC97H、Hepa1-6和H22细胞建立原位肝细胞癌模型,发现ETV4高表达与TNM分期高、肿瘤分化差、微血管侵犯及预后差正相关;ETV4反式激活PD-L1和CCL2,增加肿瘤相关巨噬细胞和髓源性抑制细胞浸润、抑制CD8+ T细胞积聚,从而促进转移;抗PD-L1联合FGFR4抑制剂BLU-554或MAPK抑制剂曲美替尼可显著抑制FGF19-ETV4信号诱导的肝细胞癌转移。

要点

  • ETV4高表达与肝细胞癌TNM分期高、分化差、微血管侵犯及预后差正相关。
  • ETV4通过反式激活PD-L1和CCL2增加TAM和MDSC浸润、抑制CD8+ T细胞积聚促进转移。
  • 抗PD-L1联合FGFR4抑制剂BLU-554或MAPK抑制剂曲美替尼显著抑制FGF19-ETV4信号介导的肝细胞癌转移。

核心结论

  • ETV4是肝细胞癌的预后生物标志物。
  • 抗PD-L1联合FGFR4抑制剂BLU-554或MAPK抑制剂曲美替尼可能是抑制肝细胞癌转移的有效策略。

研究设计与样本

  • 使用PLC/PRF/5、MHCC97H、Hepa1-6和H22细胞建立原位肝细胞癌模型。
  • 使用氯膦酸盐脂质体在C57BL/6小鼠中清除巨噬细胞。
  • 使用Gr-1单克隆抗体在C57BL/6小鼠中清除髓源性抑制细胞(MDSC)。
  • 采用流式细胞术和免疫荧光检测肿瘤微环境中关键免疫细胞的变化。

主要发现

  • ETV4表达与人类肝细胞癌更高的TNM分期、较差的肿瘤分化、微血管侵犯和不良预后正相关。
  • 肝细胞癌细胞中ETV4过表达反式激活PD-L1和CCL2表达,增加肿瘤相关巨噬细胞(TAM)和MDSC浸润并抑制CD8+ T细胞积聚。
  • 慢病毒敲低CCL2或CCR2抑制剂CCX872处理可削弱ETV4诱导的TAM和MDSC浸润及肝细胞癌转移。
  • FGF19/FGFR4和HGF/c-MET通过ERK1/2通路共同上调ETV4表达;ETV4上调FGFR4表达,下调FGFR4可减少ETV4增强的肝细胞癌转移,形成FGF19-ETV4-FGFR4正反馈环路。
  • 抗PD-L1联合FGFR4抑制剂BLU-554或MAPK抑制剂曲美替尼显著抑制FGF19-ETV4信号诱导的肝细胞癌转移。

临床怎么用

  • 作者认为抗PD-L1联合FGFR4抑制剂BLU-554或MAPK抑制剂曲美替尼可能是抑制肝细胞癌转移的有效策略。
  • 本临床前研究为开发肝细胞癌患者新型联合免疫治疗策略提供理论基础。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metastasis remains the major reason for the high mortality of patients with hepatocellular carcinoma (HCC). This study was designed to investigate the role of E-twenty-six-specific sequence variant 4 (ETV4) in promoting HCC metastasis and to explore a new combination therapy strategy for ETV4-mediated HCC metastasis. METHODS: PLC/PRF/5, MHCC97H, Hepa1-6, and H22 cells were used to establish orthotopic HCC models. Clodronate liposomes were used to clear macrophages in C57BL/6 mice. Gr-1 monoclonal antibody was used to clear myeloid-derived suppressor cells (MDSCs) in C57BL/6 mice. Flow cytometry and immunofluorescence were used to detect the changes of key immune cells in the tumour microenvironment. RESULTS: ETV4 expression was positively related to higher tumour-node-metastasis (TNM) stage, poor tumour differentiation, microvascular invasion, and poor prognosis in human HCC. Overexpression of ETV4 in HCC cells transactivated PD-L1 and CCL2 expression, which increased tumour-associated macrophage (TAM) and MDSC infiltration and inhibited CD8+ T-cell accumulation. Knockdown of CCL2 by lentivirus or CCR2 inhibitor CCX872 treatment impaired ETV4-induced TAM and MDSC infiltration and HCC metastasis. Furthermore, FGF19/FGFR4 and HGF/c-MET jointly upregulated ETV4 expression through the ERK1/2 pathway. Additionally, ETV4 upregulated FGFR4 expression, and downregulation of FGFR4 decreased ETV4-enhanced HCC metastasis, which created a FGF19-ETV4-FGFR4 positive feedback loop. Finally, anti-PD-L1 combined with FGFR4 inhibitor BLU-554 or MAPK inhibitor trametinib prominently inhibited FGF19-ETV4 signalling-induced HCC metastasis. CONCLUSIONS: ETV4 is a prognostic biomarker, and anti-PD-L1 combined with FGFR4 inhibitor BLU-554 or MAPK inhibitor trametinib may be effective strategies to inhibit HCC metastasis. IMPACT AND IMPLICATIONS: Here, we reported that ETV4 increased PD-L1 and chemokine CCL2 expression in HCC cells, which resulted in TAM and MDSC accumulation and CD8+ T-cell inhibition to facilitate HCC metastasis. More importantly, we found that anti-PD-L1 combined with FGFR4 inhibitor BLU-554 or MAPK inhibitor trametinib markedly inhibited FGF19-ETV4 signalling-mediated HCC metastasis. This preclinical study will provide a theoretical basis for the development of new combination immunotherapy strategies for patients with HCC.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Xie M, Lin Z, Ji X, et al. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol. 2023. PMID: 36907560. doi:10.1016/j.jhep.2023.02.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。